What I Need To Know About Hepatitis A

The seventh edition of the Canadian Immunization Guide was developed by the National Advisory Committee on Immunization (NACI), with the support ofthe Immunization and Respiratory Infections Division, Public Health Agency of Canada, to provide updated information and recommendations on the use of vaccines in Canada. The Public Health Agency of Canada conducted a survey in 2004, which confi rmed that the Canadian Immunization Guide is a very useful and reliable resource of information on immunization.

Hepatitis A is a liver disease. Hepatitis means inflammation of the liver. Inflammation is the painful, red swelling that results when tissues of the body become injured or infected. Inflammation can cause organs to not work properly. This publication by the National Institutes of Health (Publication No. 09-4244) provides information about the causes, symptoms, diagnosis, and treatments for Hepatitis A. Other types of hepatitis exist. The National Institutes of Health has also provided additional publications about Hepatitis B - "What I Need to Know About Hepatitis B" - Publication No. 09-4228 - and Hepatitis C - "What I Need to Know About Hepatitis C" - Publication No. 09-4229.

The cutting-edge new edition of the Centers for Disease Control and Prevention's famed "Yellow Book" is the most authoritative guide of its kind, with vital pre-travel healthcare tips and essential information on health risks abroad. It includes vaccination recommendations and disease prevention strategies for HIV/AIDS, cholera, hepatitis, influenza, plague, SARS, smallpox, viral hemorrhagic fevers, and many other illnesses.

The Manual for the Surveillance of Vaccine-Preventable Diseases, updated through 2013, provides current guidelines for those directly involved in surveillance of vaccine-preventable diseases, especially personnel at the local health departments. For each of the vaccine-preventable diseases, this manual includes a chapter describing the importance of rapid case identification; the importance of surveillance; disease reduction goals; case definitions (including clinical description and case classifications); epidemiologically important data to be collected during case investigation; activities for enhancing surveillance; activities for case investigation; and activities for outbreak control. Other chapters include information on surveillance indicators; surveillance data analyses; reporting adverse events following vaccination; and enhancing surveillance. In addition, the manual includes a section reserved for insertion of state-specific guidance for VPD surveillance and extensive appendices. This manual was first developed in 1996 to provide general guidance to state and local health department personnel who are involved in surveillance activities for vaccine-preventable diseases. This manual answers commonly asked questions regarding the surveillance and reporting of vaccine-preventable diseases and provides information on enhancing existing surveillance systems.

Hepatitis is a growing epidemic caused by a number of viruses labelled A to G. Each one requires a different diagnostic and therapeutic approach. Alan Berkman explains how they are contracted and how to deal with them.

The global epidemic of hepatitis B and C is a serious public health problem. Hepatitis B and C are the major causes of chronic liver disease and liver cancer in the world. In the next 10 years, 150,000 people in the United States will die from liver disease or liver cancer associated with chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infections. Today, between 800,000 and 1.4 million people in the United States have chronic hepatitis B and between 2.7 and 3.9 million have chronic hepatitis C. People most at risk for hepatitis B and C often are the least likely to have access to medical services. Reducing the rates of illness and death associated with these diseases will require greater awareness and knowledge among health care workers, improved identification of at-risk people, and improved access to medical care. Hepatitis B is a vaccine-preventable disease. Although federal public health officials recommend that all newborns, children, and at-risk adults receive the vaccine, about 46,000 new acute cases of the HBV infection emerge each year, including 1,000 in infants who acquire the infection during birth from their HBV-positive mothers. Unfortunately, there is no vaccine for hepatitis C, which is transmitted by direct exposure to infectious blood. Hepatitis and Liver Cancer identifies missed opportunities related to the prevention and control of HBV and HCV infections. The book presents ways to reduce the numbers of new HBV and HCV infections and the morbidity and mortality related to chronic viral hepatitis. It identifies priorities for research, policy, and action geared toward federal, state, and local public health officials, stakeholder, and advocacy groups and professional organizations.